MiRNA-365 and miRNA-520c-3p respond to risperidone treatment in first-episode schizophrenia after a 1 year remission

Chinese Medical Journal

Volumn 126, Issue 14, 2013, Pages 2676-2680

  Liu, Sha ^a   Yuan, Yan Bo ^a   Guan, Li Li ^a   Wei, Hui ^b   Cheng, Zhang ^a   Han, Xue ^a   Yang, Lei ^a   Pu, Cheng Cheng ^a   Yang, Fu De ^c   Lu, Zheng ^d   Deng, Hong ^e   Zhao, Jing Ping ^f   Yu, Xin ^a  

^a PEKING UNIVERSITY SIXTH HOSPITAL   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^c BEIJING HUILONGGUAN HOSPITAL   (China)

^d SHANGHAI MENTAL HEALTH CENTER   (China)

^e SICHUAN UNIVERSITY   (China)

^f CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

miRNA; Remission; Risperidone; Schizophrenia

Indexed keywords

MICRORNA; MICRORNA 365; MICRORNA 520C; RISPERIDONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL GLOBAL IMPRESSION SCALE; DISEASE SEVERITY; FEMALE; HUMAN; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; REAL TIME POLYMERASE CHAIN REACTION; REMISSION; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; MICRORNAS; RISPERIDONE; SCHIZOPHRENIA;

EID: 84880490706     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20130781     Document Type: Article

References (40)

1. Jablensky A. Prevalence and incidence of schizophrenia spectrum disorders: implications for prevention. Aust N Z J Psychiatry 2000; 34 Suppl: S26-34; discussion S35-28.
2. Tamminga CA, Holcomb HH. Phenotype of schizophrenia: a review and formulation. Mol Psychiatry 2005; 10: 27-39.
3. Joyce EM, Roiser JP. Cognitive heterogeneity in schizophrenia. Curr Opin Psychiatry 2007; 20: 268-272.
4. Turetsky BI, Calkins ME, Light GA, Olincy A, Radant AD, Swerdlow NR. Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr Bull 2007; 33: 69-94.
5. Van Os J, Kenis G, Rutten BP. The environment and schizophrenia. Nature 2010; 468: 203-212.
6. Farh KK, Grimson A, Jan C, Lewis BP, Johnston WK, Lim LP, et al. The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science 2005; 310: 1817-1821.
7. Guarnieri DJ, DiLeone RJ. MicroRNAs: a new class of gene regulators. Ann Med 2008; 40: 197-208.
8. Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 2005; 6: 376-385.
9. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233.
10. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
11. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838.
12. Xu B, Karayiorgou M, Gogos JA. MicroRNAs in psychiatric and neurodevelopmental disorders. Brain Res 2010; 1338: 78-88.
13. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006.
14. Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N, et al. Serum microRNAs are promising novel biomarkers. PLoS One 2008; 3: e3148.
15. Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, Yu L, et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 2008; 3: e3694.
16. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008; 105: 10513-10518.
17. Cui L, Qi Y, Li H, Ge Y, Zhao K, Qi X, et al. Serum microRNA expression profile distinguishes enterovirus 71 and coxsackievirus 16 infections in patients with hand-foot-and mouth disease. PLoS One 2011; 6: e27071.
18. Chen X, Hu Z, Wang W, Ba Y, Ma L, Zhang C, et al. Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis. Int J Cancer 2012; 130: 1620-1628.
19. Shi W, Du J, Qi Y, Liang G, Wang T, Li S, et al. Aberrant expression of serum miRNAs in schizophrenia. J Psychiatr Res 2012; 46: 198-204.
20. Lai CY, Yu SL, Hsieh MH, Chen CH, Chen HY, Wen CC, et al. MicroRNA expression aberration as potential peripheral blood biomarkers for schizophrenia. PLoS One 2011; 6: e21635.
21. Gardiner E, Beveridge NJ, Wu JQ, Carr V, Scott RJ, Tooney PA, et al. Imprinted DLK1-DIO3 region of 14q32 defines a schizophrenia-associated miRNA signature in peripheral blood mononuclear cells. Mol Psychiatry 2012; 17: 827-840.
22. Santarelli DM, Beveridge NJ, Tooney PA, Cairns MJ. Upregulation of dicer and microRNA expression in the dorsolateral prefrontal cortex Brodmann area 46 in schizophrenia. Biol Psychiatry 2011; 69: 180-187.
23. Kim AH, Reimers M, Maher B, Williamson V, McMichael O, McClay JL, et al. MicroRNA expression profiling in the prefrontal cortex of individuals affected with schizophrenia and bipolar disorders. Schizophr Res 2010; 124: 183-191.
24. Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009; 460: 748-752.
25. Schonrock N, Ke YD, Humphreys D, Staufenbiel M, Ittner LM, Preiss T, et al. Neuronal microRNA deregulation in response to Alzheimer's disease amyloid-beta. PLoS One 2010; 5: e11070.
26. Delay C, Calon F, Mathews P, Hebert SS. Alzheimer-specific variants in the 3'UTR of Amyloid precursor protein affect microRNA function. Mol Neurodegener 2011; 6: 70.
27. Horesh Y, Katsel P, Haroutunian V, Domany E. Gene expression signature is shared by patients with Alzheimer's disease and schizophrenia at the superior temporal gyrus. European Journal of Neurology 2011; 18: 410-424.
28. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I/P) New York: Biometrics Research, New York State Psychiatric Institute, November 2002.
29. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13: 261-276.
30. Guy W, Bonato RR. Manual for the ECDEU Assessment Battery, (2 ed). National Institute of Mental Health, Chevy Chase, Md 1970.
31. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 2000; 101: 323-329.
32. Tianmei S, Liang S, Yun'ai S, Chenghua T, Jun Y, Jia C, et al. The Chinese version of the Personal and Social Performance Scale (PSP): validity and reliability. Psychiatry Res 2011; 185: 275-279.
33. Andreasen NC, Carpenter WT Jr., Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005; 162: 441-449.
34. Xu Y, Li F, Zhang B, Zhang K, Zhang F, Huang X, et al. MicroRNAs and target site screening reveals a pre-microRNA-30e variant associated with schizophrenia. Schizophr Res 2010; 119: 219-227.
35. Miller BH, Zeier Z, Xi L, Lanz TA, Deng S, Strathmann J, et al. MicroRNA-132 dysregulation in schizophrenia has implications for both neurodevelopment and adult brain function. Proc Natl Acad Sci U S A 2012; 109: 3125-3130.
36. Kocerha J, Faghihi MA, Lopez-Toledano MA, Huang J, Ramsey AJ, Caron MG, et al. MicroRNA-219 modulates NMDA receptor-mediated neurobehavioral dysfunction. Proc Natl Acad Sci U S A 2009; 106: 3507-3512.
37. Baudry A, Mouillet-Richard S, Schneider B, Launay JM, Kellermann O. miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants. Science 2010; 329: 1537-1541.
38. Rong H, Liu TB, Yang KJ, Yang HC, Wu DH, Liao CP, et al. MicroRNA-134 plasma levels before and after treatment for bipolar mania. J Psychiatr Res 2011; 45: 92-95.
39. Zhou R, Yuan P, Wang Y, Hunsberger JG, Elkahloun A, Wei Y, et al. Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology 2009; 34: 1395-1405.
40. Perkins DO, Jeffries CD, Jarskog LF, Thomson JM, Woods K, Newman MA, et al. microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder. Genome Biol 2007; 8: R27.